Literature DB >> 28428106

GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.

Satoshi Inoue1, Taichi Mizushima1, Kazutoshi Fujita2, Abdelrazak Meliti3, Hiroki Ide4, Seiji Yamaguchi5, Hiroaki Fushimi6, George J Netto4, Norio Nonomura7, Hiroshi Miyamoto8.   

Abstract

Immunohistochemistry of a transcription factor, GATA3, has been widely used as a promising urothelial marker in diagnostic surgical pathology practice. However, the expression status of GATA3 in upper urinary tract urothelial carcinomas (UUTUCs) and its prognostic significance have not been fully investigated. We immunohistochemically stained for GATA3 in 99 UUTUC samples and paired nonneoplastic urothelial tissues. GATA3 was positive in 51 (51.5%; 32 [32.3%] weak, 11 [11.1%] moderate, 8 [8.1%] strong) of 99 UUTUCs, which was significantly lower than in benign urothelium (79 [96.3%] of 82; 33 [40.2%] weak, 35 [42.7%] moderate, 11 [13.4%] strong; P<.001). However, there were no statistically significant associations between GATA3 expression and tumor grade, pT stage, lymph node involvement, or distant metastasis. Meanwhile, the rate of GATA3 positivity was significantly higher (P=.004) in ureteral tumors (66.0%) than in renal pelvic tumors (35.6%). Kaplan-Meier and log-rank tests revealed that GATA3 negativity was significantly associated with lower recurrence-free survival (P=.037 for all cases, P=.026 for muscle-invasive tumors) and cancer-specific survival (P=.007 for all cases, P=.012 for muscle-invasive tumors, P=.035 for cases with adjuvant chemotherapy) rates. Multivariate analysis further identified strong correlations of GATA3 expression with tumor progression (all cases: hazard ratio [HR], 0.479 [95% confidence interval {CI},0.229-1.003; P=.051]; muscle-invasive tumors: HR, 0.387 [95% CI, 0.166-0.903; P=.028) or cancer-specific mortality (all cases: HR, 0.354 [95% CI, 0.135-0.925; P=.034]; muscle-invasive tumors: HR, 0.402 [95% CI, 0.149-1.086; P=.072]). Thus, compared with nonneoplastic urothelium, a significant decrease in the expression of GATA3 in UUTUC was seen. Moreover, loss of GATA3 expression was found to be an independent predictor of poor patient outcomes. Of note was that only roughly half of high-grade and/or muscle-invasive UUTUCs were immunoreactive for GATA3.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GATA3; Immunohistochemistry; Prognosis; Sex hormone receptors; Upper urinary tract urothelial carcinoma

Mesh:

Substances:

Year:  2017        PMID: 28428106     DOI: 10.1016/j.humpath.2017.04.003

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  12 in total

1.  Expression status of GATA3 and mismatch repair proteins in upper tract urothelial carcinoma.

Authors:  Yue Wang; Jinxia Zhang; Yunfan Wang; Shufang Wang; Yu Zhang; Qi Miao; Fei Gao; Huiying He
Journal:  Front Med       Date:  2019-04-24       Impact factor: 4.592

2.  Trop-2 in Upper Tract Urothelial Carcinoma.

Authors:  Eisuke Tomiyama; Kazutoshi Fujita; Kosuke Nakano; Ken Kuwahara; Takafumi Minami; Taigo Kato; Koji Hatano; Atsunari Kawashima; Motohide Uemura; Tetsuya Takao; Hiroaki Fushimi; Kotoe Katayama; Seiya Imoto; Kazuhiro Yoshimura; Ryoichi Imamura; Hirotsugu Uemura; Norio Nonomura
Journal:  Curr Oncol       Date:  2022-05-30       Impact factor: 3.109

3.  Expression of Phospho-ELK1 and Its Prognostic Significance in Urothelial Carcinoma of the Upper Urinary Tract.

Authors:  Satoshi Inoue; Hiroki Ide; Kazutoshi Fujita; Taichi Mizushima; Guiyang Jiang; Takashi Kawahara; Seiji Yamaguchi; Hiroaki Fushimi; Norio Nonomura; Hiroshi Miyamoto
Journal:  Int J Mol Sci       Date:  2018-03-08       Impact factor: 5.923

4.  STAT3 expression is a prognostic marker in upper urinary tract urothelial carcinoma.

Authors:  Kyosuke Matsuzaki; Kazutoshi Fujita; Yujiro Hayashi; Makoto Matsushita; Satoshi Nojima; Kentaro Jingushi; Taigo Kato; Atsunari Kawashima; Takeshi Ujike; Akira Nagahara; Motohide Uemura; Ryoichi Imamura; Seiji Yamaguchi; Hiroaki Fushimi; Hiroshi Miyamoto; Eiichi Morii; Norio Nonomura
Journal:  PLoS One       Date:  2018-08-09       Impact factor: 3.240

Review 5.  The Role of Glucocorticoid Receptor Signaling in Bladder Cancer Progression.

Authors:  Hiroki Ide; Satoshi Inoue; Hiroshi Miyamoto
Journal:  Cancers (Basel)       Date:  2018-12-04       Impact factor: 6.639

6.  Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer.

Authors:  Chung-Chieh Wang; Yu-Chieh Tsai; Yung-Ming Jeng
Journal:  PLoS One       Date:  2019-08-30       Impact factor: 3.240

7.  HDAC8 suppresses the epithelial phenotype and promotes EMT in chemotherapy-treated basal-like breast cancer.

Authors:  Garyfallia Pantelaiou-Prokaki; Iga Mieczkowska; Geske E Schmidt; Sonja Fritzsche; Evangelos Prokakis; Julia Gallwas; Florian Wegwitz
Journal:  Clin Epigenetics       Date:  2022-01-11       Impact factor: 6.551

8.  Non-Muscle Invasive Papillary Urothelial Carcinoma Metastatic to the Mandible.

Authors:  Noah Frydenlund; Yousef Zakharia; Rohan Garje; Laila Dahmoush; Michael A O'Donnell
Journal:  J Investig Med High Impact Case Rep       Date:  2018-10-16

Review 9.  Development and Carcinogenesis: Roles of GATA Factors in the Sympathoadrenal and Urogenital Systems.

Authors:  Takashi Moriguchi
Journal:  Biomedicines       Date:  2021-03-15

Review 10.  The prognostic role of steroid hormone receptor signaling pathways in urothelial carcinoma.

Authors:  Yujiro Nagata; Hiroshi Miyamoto
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.